Export

Sofosbuvir
Essential medicine status
General description
Sofosbuvir, a nucleotide polymerase inhibitor, is a pan-genotypic direct acting antiviral agent for the treatment of chronic hepatitis C virus (HCV) infection.
INN
Sofosbuvir
Medicine type
Chemical agent
EML status history
First added in 2015 (TRS 994) for Chronic hepatitis C
Added in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Wikipedia
DrugBank
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
  • Oral > Solid: 400 mg tablet